Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex

07-Nov-2012 - Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a ...

Medivir: Phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055

24-Sep-2012 - Medivir AB announced that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly ...

Medivir acquires preclinical antiviral programs including hepatitis C and prodrug technologies

07-Sep-2012 - Medivir AB announced that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir’s hepatitis C platform and know how.The acquired portfolio of research stage ...

Medivir has initiated a phase I clinical trial with its cathepsin K inhibitor MIV-711

30-May-2012 - Medivir AB announced that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases. Maris Hartmanis, CEO of ...

New Executive Vice President Commercial for Medivir

18-May-2012 - Medivir AB announced that it has appointed Henric Juserius to be the new head of the company's commercial activities. Henric, who will have overall responsibility for Medivir’s pharmaceutical marketing and sales, will join the company in August 2012 and will be part of the management team.Henric ...

Medivir announces new studies in phase III program for TMC435

Study in previous non-responder Hepatitis C genotype-1 infected patients

15-Mar-2012 - Medivir AB announced that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, ...

Medivir's TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients

07-Dec-2011 - Medivir AB announced that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company. TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will be investigated in ...

Medivir Strengthens its Management Team

01-Sep-2011 - Medivir AB announced several new appointments to its executive management team. Dr Maris Hartmanis has been appointed to Medivir’s management team as deputy CEO and COO (Chief Operating Officer). In parallel to this appointment Maris Hartmanis will continue to work as CEO of Biophausia, the ...

Medivir subsidiary BioPhausia AB sells generics business

29-Aug-2011 - Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m. The staff of BMM Pharma will not transfer in the acquisition. “This ...

Medivir's TMC649128 enters Phase Ib Trial in Patients Chronically Infected with Genotype-1 Hepatitis C Virus

24-Jun-2011 - Medivir AB announced the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.TMC649128 is a nucleoside NS5B polymerase inhibitor developed in collaboration with Tibotec Pharmaceuticals. TMC649128 has demonstrated an ...